ArticleAnnals of the rheumatic diseases2007
Consensus statement on the use of rituximab in patients with rheumatoid arthritis.
Article in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Rituximab for thyroid-associated ophthalmopathy.The Cochrane database of systematic reviews · 2022Pooled it
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Annals of the rheumatic diseases · 2011Pooled it
- Trial
- Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).Rheumatology (Oxford, England) · 2010Trial
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.Annals of the rheumatic diseases · 2008Trial
- CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study.Oral diseases · 2026Article
- Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
- Rituximab induced lung injury.BMC pulmonary medicine · 2025Article
- Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease.Journal of clinical medicine · 2025Review
- Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study.European journal of pediatrics · 2024Article
- Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.Journal of clinical medicine · 2023Review
- Article
- Review
- Review
- Insights Into the Concept of Rheumatoid Arthritis Flare.Frontiers in medicine · 2022Review
- Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).Experimental and therapeutic medicine · 2021Review
- Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2021Review
- Expression of NK (CD16+56+) and B cells (CD19) Receptor Molecules as a Reliable Clinical Response Biomarkers of SLE and RA Patients Under the Rituximab Treatment.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2019Article
- Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany.Zeitschrift fur Rheumatologie · 2019Article
- Current Therapeutic Options in the Treatment of Rheumatoid Arthritis.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.